Literature DB >> 24615780

Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia.

Lorenzo Falchi1, Michael J Keating, Edith M Marom, Mylene T Truong, Ellen J Schlette, Rachel L Sargent, Long Trinh, Xuemei Wang, Susan C Smith, Nitin Jain, Zeev Estrov, Susan O'Brien, William G Wierda, Susan Lerner, Alessandra Ferrajoli.   

Abstract

Richter syndrome (RS) is associated with poor outcome. The prognosis of patients with histologically aggressive chronic lymphocytic leukemia (CLL), or HAC, has not been studied. We aimed to correlate 2-deoxy-2-[(18)F]fluoroglucose/positron emission tomography (FDG/PET) data, histological diagnosis, clinical characteristics, and survival in patients with CLL. A total of 332 patients with CLL were histologically classified as: 95 RS, 117 HAC, and 120 histologically indolent CLL (HIC). HAC and RS patients had higher maximum standardized uptake value (SUVmax), more frequent constitutional symptoms, poorer performance status (PS), lower hemoglobin and platelets, and higher lactate dehydrogenase and β-2-microglobulin. An SUVmax ≥10 strongly correlated with mortality (overall survival [OS], 56.7 vs 6.9 months in patients with SUVmax <10 vs ≥10). Survival of patients with RS and HAC was similar among patients with SUVmax <10 or ≥10. SUVmax ≥10, PS ≥2, bulky disease, and age ≥65 were independently associated with shorter OS. In patients undergoing both fine-needle aspiration and biopsy, the former proved diagnostically inadequate in 23%, 29%, and 53% of HIC, HAC, and RS, respectively. FDG/PET is a useful diagnostic tool in patients with CLL and suspected transformation. Patients with HAC show different characteristics and worse prognosis compared with those with HIC. Patients with different CLL phases, but similar SUVmax have similar outcome. Tissue biopsy should be preferred for diagnosing RS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24615780      PMCID: PMC4123418          DOI: 10.1182/blood-2013-11-536169

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine.

Authors:  H R Schelbert; C K Hoh; H D Royal; M Brown; M N Dahlbom; F Dehdashti; R L Wahl
Journal:  J Nucl Med       Date:  1998-07       Impact factor: 10.057

2.  Limitations of Gallium-67 SPECT in histological transformation of chronic lymphocytic leukaemia: an analysis of 13 patients with clinically suspected Richter's syndrome.

Authors:  Francesc Cobo; Laura Rosiñol; Antonio Martínez; Francisco Martín; Jordi Esteve; Marta Gómez; Elisabet Nadal; Francesc Bosch; Francisco Javier Setoain; Elías Campo; Emili Montserrat
Journal:  Br J Haematol       Date:  2002-11       Impact factor: 6.998

3.  Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.

Authors:  Heiko Schöder; Ariela Noy; Mithat Gönen; Lijun Weng; David Green; Yusuf E Erdi; Steven M Larson; Henry W D Yeung
Journal:  J Clin Oncol       Date:  2005-04-18       Impact factor: 44.544

4.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

5.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

6.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

7.  Richter's syndrome: a report on 39 patients.

Authors:  L E Robertson; W Pugh; S O'Brien; H Kantarjian; C Hirsch-Ginsberg; A Cork; P McLaughlin; F Cabanillas; M J Keating
Journal:  J Clin Oncol       Date:  1993-10       Impact factor: 44.544

8.  Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.

Authors:  Apostolia M Tsimberidou; Hagop M Kantarjian; Jorge Cortes; Deborah A Thomas; Stefan Faderl; Guillermo Garcia-Manero; Srdan Verstovsek; Alessandra Ferrajoli; William Wierda; Yesid Alvarado; Susan M O'Brien; Maher Albitar; Michael J Keating; Francis J Giles
Journal:  Cancer       Date:  2003-04-01       Impact factor: 6.860

9.  Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.

Authors:  Apostolia M Tsimberidou; Susan M O'Brien; Jorge E Cortes; Stefan Faderl; Michael Andreeff; Hagop M Kantarjian; Michael J Keating; Francis J Giles
Journal:  Leuk Lymphoma       Date:  2002-04

10.  Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome.

Authors:  Giulia Fabbri; Hossein Khiabanian; Antony B Holmes; Jiguang Wang; Monica Messina; Charles G Mullighan; Laura Pasqualucci; Raul Rabadan; Riccardo Dalla-Favera
Journal:  J Exp Med       Date:  2013-10-14       Impact factor: 14.307

View more
  36 in total

Review 1.  The biology behind PI3K inhibition in chronic lymphocytic leukaemia.

Authors:  Valentín Ortiz-Maldonado; Marcial García-Morillo; Julio Delgado
Journal:  Ther Adv Hematol       Date:  2015-02

Review 2.  Richter transformation in the era of novel agents.

Authors:  Wei Ding
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia.

Authors:  Preetesh Jain; Shimin Hu; Elias Jabbour; Koichi Takahashi; Naveen Pemmaraju; Susan O'Brien; Victor Eduardo Mulanovich; Zeev Estrov
Journal:  Am J Hematol       Date:  2015-08       Impact factor: 10.047

Review 4.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

5.  Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.

Authors:  Andrew D Zelenetz; Leo I Gordon; William G Wierda; Jeremy S Abramson; Ranjana H Advani; C Babis Andreadis; Nancy Bartlett; John C Byrd; Myron S Czuczman; Luis E Fayad; Richard I Fisher; Martha J Glenn; Thomas M Habermann; Nancy Lee Harris; Richard T Hoppe; Steven M Horwitz; Christopher R Kelsey; Youn H Kim; Susan Krivacic; Ann S LaCasce; Auayporn Nademanee; Pierluigi Porcu; Oliver Press; Rachel Rabinovitch; Nishitha Reddy; Erin Reid; Ayman A Saad; Lubomir Sokol; Lode J Swinnen; Christina Tsien; Julie M Vose; Lynn Wilson; Joachim Yahalom; Nadeem Zafar; Mary Dwyer; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2015-03       Impact factor: 11.908

6.  PET-positive lymphadenopathy in CLL-Not always Richter transformation.

Authors:  Naveen Pemmaraju; Preetesh Jain; L Jeffrey Medeiros; Jeffrey L Jorgenson; Nitin Jain; Jason Willis; Dimitrios P Kontoyiannis; Zeev Estrov; William G Wierda
Journal:  Am J Hematol       Date:  2017-02-07       Impact factor: 10.047

Review 7.  FDG-PET imaging in hematological malignancies.

Authors:  L Valls; C Badve; S Avril; K Herrmann; P Faulhaber; J O'Donnell; N Avril
Journal:  Blood Rev       Date:  2016-04-16       Impact factor: 8.250

Review 8.  Risk factors for Richter syndrome in chronic lymphocytic leukemia.

Authors:  Sameer A Parikh; Tait D Shanafelt
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

Review 9.  Metabolism pathways in chronic lymphocytic leukemia.

Authors:  Uri Rozovski; Inbal Hazan-Halevy; Merav Barzilai; Michael J Keating; Zeev Estrov
Journal:  Leuk Lymphoma       Date:  2015-12-08

Review 10.  Treatment of Richter's Syndrome.

Authors:  Adalgisa Condoluci; Davide Rossi
Journal:  Curr Treat Options Oncol       Date:  2017-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.